Cambridge Investment Research Advisors Inc. increased its stake in Biosig Technologies, Inc. (NASDAQ:BSGM - Free Report) by 966.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 266,435 shares of the company's stock after purchasing an additional 241,447 shares during the period. Cambridge Investment Research Advisors Inc. owned approximately 1.55% of Biosig Technologies worth $160,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BSGM. Legacy Investment Solutions LLC bought a new stake in shares of Biosig Technologies in the 4th quarter valued at about $5,369,000. PFG Investments LLC raised its holdings in shares of Biosig Technologies by 43.5% in the 1st quarter. PFG Investments LLC now owns 158,286 shares of the company's stock valued at $95,000 after purchasing an additional 48,000 shares during the period. Millennium Management LLC bought a new position in Biosig Technologies in the 4th quarter valued at about $228,000. Geode Capital Management LLC bought a new position in Biosig Technologies in the 4th quarter valued at about $143,000. Finally, Integrity Wealth Advisors Inc. bought a new position in Biosig Technologies in the 4th quarter valued at about $61,000. 7.16% of the stock is owned by institutional investors and hedge funds.
Biosig Technologies Stock Performance
Shares of NASDAQ BSGM traded down $0.88 during trading hours on Tuesday, hitting $4.58. 1,577,096 shares of the stock were exchanged, compared to its average volume of 425,309. Biosig Technologies, Inc. has a 1-year low of $0.23 and a 1-year high of $14.11. The company's fifty day simple moving average is $5.76 and its two-hundred day simple moving average is $2.60.
Biosig Technologies (NASDAQ:BSGM - Get Free Report) last announced its earnings results on Monday, May 19th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). As a group, research analysts expect that Biosig Technologies, Inc. will post -0.88 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, Ascendiant Capital Markets increased their target price on shares of Biosig Technologies from $2.50 to $10.00 and gave the stock a "buy" rating in a research report on Friday, June 6th.
Read Our Latest Analysis on BSGM
Biosig Technologies Company Profile
(
Free Report)
BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.
Further Reading
Before you consider Biosig Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biosig Technologies wasn't on the list.
While Biosig Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
